Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I like this one a lot. Strong revenues. Possible FDA approval for treosulfan (sp?) in august which could add another $150+ million in revenues plus nasdaq uplisting. Very undervalued
started a new position last week and up about 10%, added more today. plan to hold this one for a long time, undervalued for revenue. thanks to archer for the callout.